NASDAQ:DXCM
Dexcom (DXCM)
Financials 
Technical Analysis 
May 28, 2026, 12:00 amThis summary was created by AI, based on 4 opinions in the last 12 months.
Dexcom (DXCM) continues to be seen as a promising investment opportunity by several analysts, given its position as a leading manufacturer of continuous glucose monitoring systems. The company showcases significant growth potential, particularly among diabetic and pre-diabetic patients, and has recently reported impressive revenue growth exceeding 20%. Analysts observe that Dexcom's free cash flow has doubled in the past two years, surpassing $1 billion. Despite trading at a high earnings multiple, the company's strong return on equity and continued expansion in market share signal robust long-term prospects. However, some analysts suggest maintaining cautious optimism with stop-loss recommendations, reflecting the volatility experienced in the stock's recent performance.
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium contentPremium contentWe reiterate DXCM as a TOP PICK. The manufacture of continuous glucose monitors sees plenty of growth opportunity ahead for diabetic patients using GLP-1 medicines to monitor blood sugar levels along with those pre-diabetic patients using an over-the-counter monitoring device trying to avoid the disease. Recently reported earnings showed a 22% growth in revenues and free cash flow has doubled over the last two years to exceed $1 billion. We recommend trailing up the stop (from $49) to $56, looking to achieve $86 -- upside potential of 22%. Yield 0%
(Analysts’ price target is $86.42)Premium contentDXCM is the leading maker of continuous glucose monitoring systems in the US. With diabetes being the fastest growing health issue, and only 1% of those affected having access to this type of monitoring, they have a long, long runway for growth. They have developed devices for the larger Type 2 (non-insulin using) group and has been very successful at securing insurance company inclusion. Recently reported revenue growth exceeded 20% and cash reserves are growing, while the company buys back shares. It trades at a heady 35x earnings, but the 30% ROE demonstrates its strong market dominance. We recommend setting a stop-loss at $49, looking to achieve $85 -- upside potential of 32%. Yield 0%
(Analysts’ price target is $85.35)
DXCM has been hit hard as investors fear new success of weight loss drugs will reduce demand for diabetes monitoring products. DXCM is not alone in the decline. But it is still growing, and recent comments by analysts suggest the sell off is quite overdone. It has new products on tap and is strong financially. Market share remains robust. Best Buy has started selling its products (not material on its own, but shows an expanding footprint). We would see DXCM as worth holding. Because it is 33X as large was WELL, they are hard to compare. WELL, being smaller, could potentially rise more, but comes with much more overall risk. From a safety and valuation standpoint, we would, today, prefer DXCM.
Unlock Premium - Try 5i Free
- «
- ‹
- 1
- ›
- »
Dexcom (DXCM) Frequently Asked Questions
What is Dexcom stock symbol?
Dexcom is a American stock, trading under the symbol DXCM (previously DXCM-Q on Stockchase) on the NASDAQ (DXCM). It is usually referred to as NASDAQ:DXCM or DXCM
Is Dexcom a buy or a sell?
In the last year, 2 stock analysts published opinions about DXCM (previously DXCM-Q on Stockchase). 2 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is HOLD. Read the latest stock experts' ratings for Dexcom.
Is Dexcom a good investment or a top pick?
Dexcom was recommended as a Top Pick by James Telfser on 2020-10-15. Read the latest stock experts ratings for Dexcom.
Why is Dexcom stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for help on deciding if you should buy, sell or hold the stock.
Is Dexcom worth watching?
2 stock analysts on Stockchase covered Dexcom in the last year. It is a trending stock that is worth watching.
What is Dexcom stock price?
On 2026-05-28, Dexcom (DXCM) stock closed at a price of $71.93.
Our PAST TOP PICK with DXCM has triggered its stop at $62. To remain disciplined, we recommend covering the position at this time.